Addressing unmet needs in oncology

Targeted therapeutics, patient selection,
and execution that drives value.

Read more

Lead Oncology Products


Multi-targeted kinase inhibitor

MGCD265 targets the receptor tyrosine kinases (RTKs) Met, VEGFR 1,2,3 and Axl, as well as Tie2 and Ron. These kinases play key roles in tumor development, survival and metastasis as well as angiogenesis. Read more


Novel multi-target kinase inhibitor

MGCD516 targets members of the Eph receptor family, Met, Ret and VEGFR 1, 2, 3. The inclusion of Eph and Ret as targets, in addition to Met, is important due to their overexpression and/or mutation in a number of cancers. Read more


Spectrum-selective HDAC inhibitor

Mocetinostat targets a subset of class I histone deacetylases (HDACs). Inhibition of these cancer-related isoforms results in multiple and desirable anti-cancer effects. Read more

Message from Charles M. Baum, MD, PhD, President and CEO

“ I joined the Company because I recognize the value of the pipeline and the opportunity of our clinical portfolio to address unmet needs in oncology. ”

Read more

Corporate Presentation

Corporate Presentation – June 2014

Stock Information


Disclaimer | Privacy Policy | © Mirati Therapeutics, 2013.
Website design: Solo Communications

Subscribe to News

Please fill out the form below to be added to Mirati's press release distribution list.

Your Name (required)

Your Company

Your Email (required)